These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36752206)

  • 41. Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice.
    Lee SM; Muratalla J; Karimi S; Diaz-Ruiz A; Frutos MD; Guzman G; Ramos-Molina B; Cordoba-Chacon J
    Cell Mol Life Sci; 2023 Jan; 80(2):39. PubMed ID: 36629912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis.
    Lei Z; Yu J; Wu Y; Shen J; Lin S; Xue W; Mao C; Tang R; Sun H; Qi X; Wang X; Xu L; Wei C; Wang X; Chen H; Hao P; Yin W; Zhu J; Li Y; Wu Y; Liu S; Liang H; Chen X; Su C; Zhou S
    J Hepatol; 2024 Feb; 80(2):194-208. PubMed ID: 38438948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.
    Cynis H; Kehlen A; Haegele M; Hoffmann T; Heiser U; Fujii M; Shibazaki Y; Yoneyama H; Schilling S; Demuth HU
    Int J Exp Pathol; 2013 Jun; 94(3):217-25. PubMed ID: 23560443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemokine receptor CCR1 regulates macrophage activation through mTORC1 signaling in nonalcoholic steatohepatitis.
    Li H; Pan T; Gao L; Ding R; Yu Y; Ma M; Wang Y; Jin S; Chen Y; Ding C; Xu L
    Metabolism; 2024 Feb; 151():155758. PubMed ID: 38070823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatocyte CD36 protects mice from NASH diet-induced liver injury and fibrosis via blocking N1ICD production.
    Li Y; Zhang L; Jiao J; Ding Q; Li Y; Zhao Z; Luo J; Chen Y; Ruan X; Zhao L
    Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166800. PubMed ID: 37423141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling.
    Li Y; Xiu W; Xu J; Chen X; Wang G; Duan J; Sun L; Liu B; Xie W; Pu G; Wang Q; Wang C
    JCI Insight; 2022 Dec; 7(23):. PubMed ID: 36477358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction.
    Cordoba-Chacon J; Sarmento-Cabral A; Del Rio-Moreno M; Diaz-Ruiz A; Subbaiah PV; Kineman RD
    Endocrinology; 2018 Nov; 159(11):3761-3774. PubMed ID: 30295789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis.
    Csak T; Bala S; Lippai D; Satishchandran A; Catalano D; Kodys K; Szabo G
    Liver Int; 2015 Feb; 35(2):532-41. PubMed ID: 25040043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver.
    Gopal T; Kumar N; Perriotte-Olson C; Casey CA; Donohue TM; Harris EN; Talmon G; Kabanov AV; Saraswathi V
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G428-G438. PubMed ID: 31928222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.
    Kim TH; Banini BA; Asumda FZ; Campbell NA; Hu C; Moser CD; Shire AM; Han S; Ma C; Krishnan A; Mounajjed T; White TA; Gores GJ; LeBrasseur NK; Charlton MR; Roberts LR
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G333-G344. PubMed ID: 32683952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protective and Detrimental Roles of p38α Mitogen-Activated Protein Kinase in Different Stages of Nonalcoholic Fatty Liver Disease.
    Hwang S; Wang X; Rodrigues RM; Ma J; He Y; Seo W; Park SH; Kim SJ; Feng D; Gao B
    Hepatology; 2020 Sep; 72(3):873-891. PubMed ID: 32463484
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
    Wolff G; Sakurai M; Mhamane A; Troullinaki M; Maida A; Deligiannis IK; Yin K; Weber P; Morgenstern J; Wieder A; Kwon Y; Sekar R; Zeigerer A; Roden M; Blüher M; Volk N; Poth T; Hackert T; Wiedmann L; De Angelis Rigotti F; Rodriguez-Vita J; Fischer A; Mukthavaram R; Limphong P; Tachikawa K; Karmali P; Payne J; Chivukula P; Ekim-Üstünel B; Martinez-Jimenez CP; Szendrödi J; Nawroth P; Herzig S
    Mol Metab; 2022 Jun; 60():101487. PubMed ID: 35378329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mitochondria- and NOX4-dependent antioxidant defense mitigates progression to nonalcoholic steatohepatitis in obesity.
    Greatorex S; Kaur S; Xirouchaki CE; Goh PK; Wiede F; Genders AJ; Tran M; Jia Y; Raajendiran A; Brown WA; McLean CA; Sadoshima J; Watt MJ; Tiganis T
    J Clin Invest; 2023 Dec; 134(3):. PubMed ID: 38060313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis.
    Galastri S; Zamara E; Milani S; Novo E; Provenzano A; Delogu W; Vizzutti F; Sutti S; Locatelli I; Navari N; Vivoli E; Caligiuri A; Pinzani M; Albano E; Parola M; Marra F
    Clin Sci (Lond); 2012 Oct; 123(7):459-71. PubMed ID: 22545719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.
    Mauer AS; Hirsova P; Maiers JL; Shah VH; Malhi H
    Am J Physiol Gastrointest Liver Physiol; 2017 Mar; 312(3):G300-G313. PubMed ID: 28039158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of the macrophage-hepatic stellate cell interaction by targeting macrophage peroxisome proliferator-activated receptor gamma to prevent non-alcoholic steatohepatitis progression in mice.
    Ni XX; Ji PX; Chen YX; Li XY; Sheng L; Lian M; Guo CJ; Hua J
    Liver Int; 2022 Dec; 42(12):2696-2712. PubMed ID: 36165186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ets-1 deficiency alleviates nonalcoholic steatohepatitis via weakening TGF-β1 signaling-mediated hepatocyte apoptosis.
    Liu D; Wang K; Li K; Xu R; Chang X; Zhu Y; Sun P; Han X
    Cell Death Dis; 2019 Jun; 10(6):458. PubMed ID: 31189885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.